"Real world" populations compared to clinical trials: can electronic record linkage be used to identify trial eligible patients?

Kelly Baillie, Christine Crearie, Tanja Mueller, Jiafeng Pan, Rob Jones, Marion Bennie, Jennifer Laskey

Research output: Contribution to journalMeeting abstractpeer-review

14 Downloads (Pure)


The Cancer Medicines Outcomes Programme aims to develop a process to determine clinical outcome data of cancer medicines in Scotland using routinely collected, electronically linked health records. Such, ‘real world’ patient populations are not necessarily directly comparable to clinical trial populations suggesting that outcome data from clinical trials may not provide a suitable benchmark. It is therefore important to be able to describe the demographics of a population to contextualise outcome data.

The aim of this study was to determine whether electronic record linkage (ERL) could be used to evaluate the potential eligibility of patients for inclusion in a relevant clinical trial.

Although many eligibility criteria used in the clinical trials could be applied to ERL, others could not. Nevertheless, ERL can be used to estimate the number of patients being treated with a specific cancer medicine who may have been eligible for inclusion in the respective trial – information that could be useful when comparing results from an observational study to clinical trial results.
Original languageEnglish
JournalJournal of Oncology Pharmacy Practice
Issue number8 (Supplement)
Early online date25 Sep 2018
Publication statusPublished - 1 Dec 2018
Event21st Annual BOPA Symposium - Birmingham, United Kingdom
Duration: 12 Oct 201814 Oct 2018

Cite this